Development of a target quality profile for capsules containing a dry extract of salvia sclarea l. grown in tajikistan
DOI:
https://doi.org/10.24959/sphhcj.23.309Keywords:
Salvia sclarea L.; clary sage; dry extract; anxiolytic activity; target drug quality profile; technology of solid dosage forms.Abstract
Aim. To work out the concept of scientific research on the pharmaceutical development of capsules based on the substance of a dry extract of Salvia sclarea L. (clary sage) grown in Tajikistan by developing a target drug quality profile.
Materials and methods. During the research, methods of a systematic approach, scientific analysis, comparison, analogy, and generalization of information on the pharmaceutical development of herbal medicines were used. Tabular and schematic tools for visual presentation of the data obtained were also applied.
Results. The pharmacological studies of a dry extract of Salvia sclarea L. grown in Tajikistan using the “elevated plus maze” test indicate the prospects of its use as an active substance of a moderate anxiolytic action in the dose of 300 mg/kg. The results obtained served as the basis for developing a target quality profile for capsules containing a dry extract as the first stage of the pharmaceutical development, implementing the programmable quality concept “Quality by Design”. When developing the target quality profile for capsules, a set of complementary provisions, recommendations, and methods of the State Pharmacopoeia of Ukraine and the Eurasian Economic Union concerning the issues of technological, chemical, and microbiological requirements for the development of pharmaceutical products was analyzed.
Conclusions. Thus, the development of a target quality profile for capsules containing a dry extract of Salvia sclarea L. will make it possible to rationally use material resources and implement the programmable quality concept.
References
Profylaktyka serdechno-sosudystykh zabolevanyi. Karmannoe posobye po otsenke y snyzhenyiu ryska serdechno-sosudystykh zabolevanyi (2007) / Vsemyrnaia orhanyzatsyia zdravookhranenyia. Zheneva.
Dolia, V. S., Trzhetsynskyi, S. D., Mozul, V. Y., Tretiak, N. Y. (2013). Osobennosty khymycheskoho sostava vydov roda Salvia L. Aktualni pytannia farmatsevtychnoi i medychnoi nauky ta praktyky, 3 (13), 083-085.
Mervić, M., Bival Štefan, M., Kindl, M., Blažeković, B., Marijan, M., Vladimir-Knežević, S. (2022). Comparative Antioxidant, Anti-Acetylcholinesterase and Anti-α-Glucosidase Activities of Mediterranean Salvia Species / M. Mervić et al. Plants (Basel), 11, 5. doi: 10.3390/plants11050625.
Imanshahidi, M., Hosseinzadeh, H. (2006). The pharmacological effects of Salvia species on the central nervous system. Phytotherapy research, 20, 6, 427–437. doi: 10.1002/ptr.1898.
Nizhenkovska, I. V. (2014). Shavliia likarska – suchasni aspekty zastosuvannia (Ohliad literatury). Botanical Therapy Chasopys, 2, 58–61.
Jasicka-Misiak, I., Poliwoda, A., Petecka, M., Buslovych, О., Shlyapnikov, V. A., Wieczorek, R. (2018). Antioxidant Phenolic Compounds in Salvia officinalis L. and Salvia sclarea L. Ecological Chemistry and Engineering S., 25, 1, 133-142. doi: 10.1515/eces-2018-0009.
Kačániová, M., Vukovic, N. L., Čmiková, N., Galovičová, L., Schwarzová, M., Šimora V. et al. (2018). Salvia sclarea: Chemical composition and biological activity. Journal of Agronomy, Technology and Engineering Management, 1, 1, 18-28.
Dyrektyva Soveta ES o sblyzhenyy zakonov, postanovlenyi y admynystryrovanye polozhenyi hosudarstv ES po voprosam zashchyty zhyvotnykh, yspolzuemykh dlia еksperymentalnykh y druhykh nauchnykh tselei (86/609/EES). Nadlezhashchaia proyzvodstvennaia praktyka lekarstvennykh sredstv (1999) / pod red. N. A. Liapunova et al. Kyiv: Moryon.
Directive 2010/63/EU of the European Parliament and of the Council dated 22 September 2010 on the protection of animals used for scientific purposes. (2010). Official Journal of the European Union L276. 33-79. URL: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri PDF.
Doklinichni doslidzhennia likarskykh zasobiv (2001) / za red. chl. kor AMN Ukrainy O. V. Stefanova. Kyiv: Avitsena.
Lapach, S. N., Chubenko, A. V., Babych, P. N. (2001). Statystycheskye metody v medyko–byolohycheskykh yssledovanyiakh s yspolzovanyem Excel. Kyiv: Moryon.
Nykytiuk, V. H., Yarnıkh, T. H., Shakyn, E. S. (2015). Farmatsevtycheskaia razrabotka v ramkakh pravyl GMP – sochetanye etapov farmrazrabotky y polozhenyi PQS. Profesiinyi menedzhment v suchasnykh umovakh rozvytku rynku : materialy dop. IV nauk.-prakt. konf. z mizhnar. Uchastiu. Kharkiv.
The Design and manufacture of medicines / ed. M. E. Aulton. London.
EMA/CHMP/ich/24235/2006. Quality Risk Management (ICH Q9), 1 January 2006. Available at: http://www.ich.org/products/guidelines.html.
EMA/INS/GMP/79818/2011. Pharmaceutical Quality System (ICH Q10), 31 January 2011. Available at: http://www.ich.org/products/guidelines.html.
EMEA/CHMP/167068/2004 – ICH. Part I: Note for guidance on pharmaceutical development (ICH Topic Q8 (R2) Pharmaceutical Development) : Part II: Annex to note for guidance on pharmaceutical development (ICH Topic Q8 Annex Pharmaceutical Development). (2009). European Medicines Agency.
Nadlezhashchaia proyzvodstvennaia praktyka lekarstvennykh sredstv. Aktyvnye farmatsevtycheskye ynhredyenty. Hotovye lekarstvennye sredstva : rukovodstvo po kachestvu. Rekomendatsyy PIC/S (2001) / pod red. N. A. Liapunovay et al. Kyiv: Moryon.
Derzhavna Farmakopeia Ukrainy (2015). v 3 t. / DP ”Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv”. 2-e vyd. Kharkiv: Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
